Bioshares 130
There is some validity to the claim that Australian investors do not recognise the potential value of biotech assets. Witness G-CSF, which was discovered in Australia but commercialised in the US and has genarated sales of US$7.3 billion for Amgen.
We suggest that a similar investment potential exists with Alchemia’s synthetic heparin, but the wider market is slow to appreciate this.
And we cover the cash positions of 81 companies that report under the 4.7B rule.
Companies covered: ACL
Bioshares 130 There is some validity to the claim that...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable